** Shares of vaccine maker Moderna MRNA.O and gene therapy developers fall between 12% and 22% after the U.S. FDA named Vinay Prasad as the director of its Center for Biologics Evaluation and Research (CBER)
** Prasad was a fierce critic of COVID-19 vaccine and mask mandates
** As the director of CBER, Prasad will oversee the regulation of vaccines and gene therapies
** Shares of Moderna down 12.4%, Novavax NVAX.O down 5.2%, while Pfizer PFE.N, previously down after an announcement on medicine costs, extends losses to 3%
** Shares of gene therapy developers such as Sarepta Therapeutics SRPT.O fall 21.5%, Taysha Gene Therapies TSHA.O fall 20.7%, Capricor Therapeutics CAPR.O down 20.3%
** U.S.-listed shares of CRISPR Therapeutics CRSP.BN down 9.6%, Solid Biosciences SLDB.O down 15.3%,
** MRNA down 41.3% and SRPT down 61.1% YTD
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。